Telmisartan Tab Hypertension
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Telmisartan (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Boehringer Ingelheim Pharmaceuticals Official(s) and/or principal investigator(s):
Boehringer Ingelheim, Study Chair, Affiliation: Boehringer Ingelheim Pharmaceuticals
Overall contact:
Boehringer Ingelheim Study Coordinator, Phone: 1-800-243-0127, Email: clintriage.rdg@boehringer-ingelheim.com
Summary
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
Clinical Details
Official title: RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.
Study design: Other, Prospective
Primary outcome: To assess the overall effect of AHT with telmisartan after approx. 12 wks in GP and SP in uncontrolled hypertensive pnts with high and very high CV risk according ESH/ESC Guidelines 2007.
Secondary outcome: Identify baseline factors, patterns of concomitant medication that can help predict effect of AHT with Telmisartan after approx. 12 weeks. Identify types prescribers who accept/or not deliberate deviation from target BP.
Detailed description:
Study Design:
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk
according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision
to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12. 5 mg or 25 mg, in
the usual way and in line with the SmPC and reimbursement criteria
Exclusion Criteria:
Contra-indications as in the Summary of Product Characteristics
Locations and Contacts
Boehringer Ingelheim Study Coordinator, Phone: 1-800-243-0127, Email: clintriage.rdg@boehringer-ingelheim.com
Boehringer ingelheim Investigational Site, Balegem, Belgium; Recruiting
Boehringer ingelheim Investigational Site, Burst, Belgium; Recruiting
Boehringer ingelheim Investigational Site 3, Dendermonde, Belgium; Recruiting
Boehringer ingelheim Investigational Site, Grembergen, Belgium; Recruiting
Boehringer ingelheim Investigational Site, Lens-Saint-Remy, Belgium; Recruiting
Boehringer ingelheim Investigational Site, Recogne, Belgium; Recruiting
Boehringer ingelheim Investigational Site, Wilrijk, Belgium; Recruiting
Additional Information
Starting date: April 2009
Last updated: September 24, 2009
|
